Jump to content

Meloxicam/rizatriptan

From Wikipedia, the free encyclopedia

Meloxicam/rizatriptan
Combination of
MeloxicamNonsteroidal anti-inflammatory drug
Rizatriptanserotonin (5-HT) 1B/1D receptor agonist (triptan)
Clinical data
Trade namesSymbravo
License data
Routes of
administration
By mouth
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG

Meloxicam/rizatriptan, sold under the brand name Symbravo, is a fixed-dose combination medication used for the treatment of migraine.[1] It is a combination of meloxicam, a nonsteroidal anti-inflammatory medication; and rizatriptan (as rizatriptan benzoate), a serotonin (5-HT) 1B/1D receptor agonist (triptan).[1] It is taken by mouth.[1]

Meloxicam/rizatriptan was approved for medical use in the United States in January 2025.[2]

Medical uses

[edit]

Meloxicam/rizatriptan is indicated for the acute treatment of migraine with or without aura in adults.[1]

Society and culture

[edit]
[edit]

Meloxicam/rizatriptan was approved for medical use in the United States in January 2025.[2]

References

[edit]
  1. ^ a b c d e https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215431s000lbl.pdf
  2. ^ a b "Axsome Therapeutics Announces FDA Approval of Symbravo (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults" (Press release). Axsome Therapeutics. 30 January 2025. Retrieved 7 February 2025 – via GlobeNewswire.
[edit]